Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 248 Show results per page	View Search Criteria \| Help With Results


1.		German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				15 to 65				Other				GMALL01 NCT00198991


2.		Efficacy of G-CSF-Priming in Elderly AML Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				Over 60				Other				AML-elderly 01/99 Trial NCT00199147

Last Modified: 11/24/2008 First Published: 7/1/1999


3.		Phase II/III Study of Standard and Novel Conditioning Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 to 70				Other				RPCI-RP-9815 NCI-V99-1527, NCT00003816, RP 98-15


4.		Stem Cell Transplant for Bone Marrow Failures

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Active				35 and under				Other				9504M09637 MT2000-18, NCT00176878


5.		Nonmyeloablative Stem Cell Transplant in Elderly

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				Over 60				Other				012000 NCT00382759


6.		Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				152CL201 NCT00391066

Last Modified: 10/31/2008 First Published: 3/22/2007


7.		Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Biomarker/Laboratory analysis, Treatment				Active				Any age				Other				UHW-AML16 EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480


8.		Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				19 to 70				Other				F080429003 UAB-0775, NCT00714259

Last Modified: 12/5/2008 First Published: 12/23/2003


9.		Phase III Randomized Study of Nonmyeloablative Conditioning Comprising Low-Dose Total Body Irradiation With Versus Without Fludarabine Followed By HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies at Low or Moderate Risk For Graft Rejection

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 75				NCI				FHCRC-1813.00 5666, NCT00075478


10.		Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 60				Other				AML_CR2_allo_HSCT NCT00125606

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute